Stay updated on Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial
Sign up to get notified when there's something new on the Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial page.

Latest updates to the Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial page
- Check2 days agoChange DetectedA new revision entry v3.3.4 was added to the record history, and the previous entry v3.3.3 was removed.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedRevision history shows the addition of Revision: v3.3.3 and the removal of HHS Vulnerability Disclosure as well as Revision: v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check52 days agoChange DetectedRevision history now shows Revision: v3.3.2 as the latest entry, and Revision: v3.2.0 has been removed.SummaryDifference0.1%

- Check59 days agoChange DetectedRemoved the banner warning about a lapse in government funding and potential downtime. The prior notice indicated that site information might not be up to date and that inquiries could be delayed.SummaryDifference0.6%

- Check74 days agoChange DetectedThe screenshots show minor UI adjustments and an additional version entry in the record history; no substantive changes to study details are observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check88 days agoChange DetectedThe page now adds current date references and a study status update, while removing an older date reference.SummaryDifference1.0%

Stay in the know with updates to Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial page.